All In Biotech

Drug Trial Radar · NCT02142959

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Jun 30, 2014

Primary completion

Apr 30, 2015

Study completion Apr 30, 2015

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
May 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis. Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy. This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.

Conditions

  • Breast Cancer

Interventions

  • Omaveloxolone Lotion 0.5%Drug

    Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

  • Omaveloxolone Lotion 3%Drug

    Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

  • Vehicle LotionDrug

    Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

  • 3D conformal radiation therapyRadiation

    45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion VehicleTime frame: Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Mesa, Arizona

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Arizona Cancer Center

    Scottsdale, Arizona

  • University of Colorado Hospital, Dept. of Radiation Oncology

    Aurora, Colorado

  • Norwalk Hospital

    Norwalk, Connecticut

  • Lakeland Regional Cancer Center

    Lakeland, Florida

  • John B. Amos Cancer Center

    Columbus, Georgia

  • St. Vincent Anderson Regional Hospital Cancer Center

    Anderson, Indiana

  • Parkview Research Center

    Fort Wayne, Indiana

  • Radiation Oncology Associates - Parkview Research Center

    Fort Wayne, Indiana

  • Northern Indiana Cancer Research Consortium

    South Bend, Indiana

  • Willis-Knighton Cancer Center

    Shreveport, Louisiana

  • University of Nebraska Medical Center - Eppley Cancer Center

    Omaha, Nebraska

  • CaroMont Health Comprehensive Cancer Center

    Gastonia, North Carolina

  • Sanford Health

    Bismarck, North Dakota

  • St. John Health System

    Tulsa, Oklahoma

  • Abington Memorial Hospital

    Abington, Pennsylvania

  • Hughes Cancer Center

    East Stroudsburg, Pennsylvania

  • Mount Nittany Medical Center

    State College, Pennsylvania

  • AnMed Health Cancer Center

    Anderson, South Carolina

  • 21st Century Oncology - Carolina Regional Cancer Center

    Myrtle Beach, South Carolina

  • Spartanburg Regional Medical Center - Gibbs Cancer Center

    Spartanburg, South Carolina

  • Sanford Research/USD

    Sioux Falls, South Dakota

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Cancer Care Northwest

    Spokane, Washington

  • Mayo Clinic - LaCrosse

    La Crosse, Wisconsin

  • Columbia St. Mary's

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.